Basis: Latest reported fiscal year. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA margin is N/A as of Tuesday, October 6, 2026.
EBITDA MARGIN
N/A
Market Cap
$12.54M
EBITDA Margin
-1106.68%
TTM Avg
-120183.14%
3Y Avg
-60445.11%
5Y Avg
-60445.11%
Market Cap
$12.39M
EBITDA Margin
-5650.91%
TTM Avg
-5650.91%
3Y Avg
-12817.85%
5Y Avg
-12817.85%
Market Cap
$12.28M
EBITDA Margin
-1.94%
TTM Avg
-1.94%
3Y Avg
-10.48%
5Y Avg
-10.95%
Market Cap
$12.90M
EBITDA Margin
-16245.70%
TTM Avg
-13416.38%
3Y Avg
-13330.05%
5Y Avg
-20098.17%
Market Cap
$12.63M
EBITDA Margin
-34.02%
TTM Avg
-37.67%
3Y Avg
-64.98%
5Y Avg
-56.41%
Market Cap
$11.61M
EBITDA Margin
-42476.19%
TTM Avg
-23876.87%
3Y Avg
-47050.54%
5Y Avg
-38398.83%
Market Cap
$13.48M
EBITDA Margin
-839.37%
TTM Avg
-1027.77%
3Y Avg
-3215.79%
5Y Avg
-3215.79%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lantern Pharma Inc. (LTRN) | $12.18M | N/A | N/A | N/A | N/A |
| Dare Bioscience, Inc. (DARE)vs › | $12.54M | -1106.68% | -120183.14% | -60445.11% | -60445.11% |
| Bullfrog AI Holdings, Inc. Common Stock (BFRG)vs › | $12.39M | -5650.91% | -5650.91% | -12817.85% | -12817.85% |
| IRIDEX Corporation (IRIX)vs › | $12.28M | -1.94% | -1.94% | -10.48% | -10.95% |
| Cellectar Biosciences, Inc. (CLRB)vs › | $12.90M | -16245.70% | -13416.38% | -13330.05% | -20098.17% |
| Cytosorbents Corporation (CTSO)vs › | $12.63M | -34.02% | -37.67% | -64.98% | -56.41% |
| Passage Bio, Inc. (PASG)vs › | $13.11M | N/A | N/A | N/A | N/A |
| Phio Pharmaceuticals Corp. (PHIO)vs › | $11.61M | -42476.19% | -23876.87% | -47050.54% | -38398.83% |
| Optimi Health Corp. (OPTH)vs › | $13.48M | -839.37% | -1027.77% | -3215.79% | -3215.79% |
| Pluri Inc. (PLUR)vs › | $11.54M | -2404.23% | -2020.23% | -5031.76% | -7490.37% |
Gross Margin
0.0%
EBITDA Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
